1.34
price up icon2.29%   0.03
after-market アフターアワーズ: 1.34
loading
前日終値:
$1.31
開ける:
$1.27
24時間の取引高:
32,790
Relative Volume:
0.23
時価総額:
$4.29M
収益:
$129.20K
当期純損益:
$-7.44M
株価収益率:
-0.1197
EPS:
-11.19
ネットキャッシュフロー:
$-8.62M
1週間 パフォーマンス:
-4.29%
1か月 パフォーマンス:
-13.55%
6か月 パフォーマンス:
-79.97%
1年 パフォーマンス:
-90.99%
1日の値動き範囲:
Value
$1.22
$1.35
1週間の範囲:
Value
$1.22
$1.42
52週間の値動き範囲:
Value
$1.22
$16.80

Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile

Name
名前
Sonnet Biotherapeutics Holdings Inc
Name
セクター
Healthcare (1164)
Name
電話
609-375-2227
Name
住所
100 OVERLOOK CENTER, PRINCETON, NJ
Name
職員
0
Name
Twitter
@SonnetBio
Name
次回の収益日
2024-08-12
Name
最新のSEC提出書
Name
SONN's Discussions on Twitter

SONN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SONN
Sonnet Biotherapeutics Holdings Inc
1.34 4.29M 129.20K -7.44M -8.62M -11.19
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Sonnet Biotherapeutics Holdings Inc (SONN) 最新ニュース

pulisher
Mar 30, 2025

Chardan Capital Reaffirms Buy Rating for Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Sonnet BioTherapeutics’ (SONN) Buy Rating Reaffirmed at Chardan Capital - The AM Reporter

Mar 29, 2025
pulisher
Mar 28, 2025

SONN stock touches 52-week low at $1.28 amid market challenges - Investing.com Australia

Mar 28, 2025
pulisher
Mar 26, 2025

Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Sonnet BioTherapeutics Successfully Completes First Safety - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

Clinical Trial Success: New Cancer Drug Combo Shows 83% Disease Control in Sarcoma Patients - Stock Titan

Mar 26, 2025
pulisher
Mar 21, 2025

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Up 16.4% in February - Defense World

Mar 21, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics secures new IL-18 patent - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics secures new IL-18 patent By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics Secures Second Patent for IL-18 Variant - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

Sonnet BioTherapeutics Receives Notice of Allowance for - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Major Patent Win: Sonnet's Revolutionary IL-18 Cancer Treatment Shows Superior Binding Properties - StockTitan

Mar 19, 2025
pulisher
Mar 11, 2025

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Sonnet BioTherapeutics Holdings, Inc. Announces Availability of On-Demand Video Webcast Following Virtual Investor "Top 5 for ‘25" Conference - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Sonnet Bio CEO Unveils 5 Game-Changing Developments Coming in 2025 - StockTitan

Mar 11, 2025
pulisher
Mar 11, 2025

XRP Plunges as Recession Panic and Crypto Summit Fallout Slam Investors - The Globe and Mail

Mar 11, 2025
pulisher
Mar 07, 2025

Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga

Mar 07, 2025
pulisher
Mar 04, 2025

SONN stock touches 52-week low at $1.33 amid market challenges - Investing.com UK

Mar 04, 2025
pulisher
Feb 27, 2025

Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Highlights Promising SON-1010 Data - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors - The Manila Times

Feb 26, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Presents Innovative FHAB® Platform Data at 2025 AACR:IO Conference - Nasdaq

Feb 26, 2025
pulisher
Feb 26, 2025

Sonnet BioTherapeutics Presents Compilation of Data - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Can This Immunotherapy Beat Solid Tumors? Sonnet's SON-1010 Shows 48% Clinical Benefit - StockTitan

Feb 26, 2025
pulisher
Feb 21, 2025

Sonnet BioTherapeutics Announces Availability of Proprietary ADC Platform for Drug Discovery Partnerships - Defense World

Feb 21, 2025
pulisher
Feb 20, 2025

Sonnet BioTherapeutics advances novel ADC platform By Investing.com - Investing.com Australia

Feb 20, 2025
pulisher
Feb 19, 2025

Sonnet BioTherapeutics advances novel ADC platform - Investing.com

Feb 19, 2025
pulisher
Feb 19, 2025

SONN stock touches 52-week low at $1.38 amid market challenges - Investing.com India

Feb 19, 2025
pulisher
Feb 19, 2025

Sonnet Biotherapeutics' Proprietary ADC Platform Available For Drug Discovery Partnerships - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Sonnet BioTherapeutics Announces That Its Proprietary - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

Sonnet BioTherapeutics Advances Antibody Drug Conjugate Platform - TipRanks

Feb 19, 2025
pulisher
Feb 19, 2025

2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street - The Globe and Mail

Feb 19, 2025
pulisher
Feb 19, 2025

Can This New ADC Platform Challenge Established Cancer Drugs? Preclinical Data Shows Promise - StockTitan

Feb 19, 2025
pulisher
Feb 18, 2025

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference - The Manila Times

Feb 18, 2025
pulisher
Feb 18, 2025

Sonnet BioTherapeutics Announces Acceptance of Poster Presentation at 2025 AACR IO Conference - Nasdaq

Feb 18, 2025
pulisher
Feb 18, 2025

Revolutionary Cancer Treatment Breakthrough: Sonnet's IL-12 Protein Research Heads to AACR 2025 - StockTitan

Feb 18, 2025
pulisher
Feb 16, 2025

Sonnet BioTherapeutics appoints new chief business officer - MSN

Feb 16, 2025
pulisher
Feb 15, 2025

Sonnet BioTherapeutics Issues Financial Results for Q4 2024, Reports Progress in Clinical Trials and Business Development - Defense World

Feb 15, 2025
pulisher
Feb 14, 2025

Sonnet Biotherapeutics Reports Increased Revenue and Strategic Developments - TipRanks

Feb 14, 2025
pulisher
Feb 14, 2025

Sonnet BioTherapeutics appoints new chief business officer By Investing.com - Investing.com Nigeria

Feb 14, 2025
pulisher
Feb 13, 2025

Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 13, 2025
pulisher
Feb 13, 2025

Sonnet BioTherapeutics Holdings, Inc. SEC 10-Q Report - TradingView

Feb 13, 2025
pulisher
Feb 13, 2025

Sonnet BioTherapeutics reports wider Q1 net loss, CFO transition - MSN

Feb 13, 2025
pulisher
Feb 13, 2025

Sonnet Biotherapeutics Appoints Stephen Mcandrew As Chief Business Officer -February 13, 2025 at 08:40 am EST - Marketscreener.com

Feb 13, 2025

Sonnet Biotherapeutics Holdings Inc (SONN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
大文字化:     |  ボリューム (24 時間):